Join
Live feed
·
PRReleasevia Quantisnow
Vistagen Therapeutics Inc. logo

Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder

ByQuantisnow·Wall Street's wire, on your screen.
VTGN· Vistagen Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VTGN (Vistagen Therapeutics Inc.) and more on Quantisnow.